|Last Update: 05/22/13 - 2:30 PM EDT|
|YTD Performance: 31.46%|
|Previous Close: $72.58|
|52 Week Range: $37.77 - $77.11|
|Oustanding Shares: 124,378,537|
|Market Cap: 9,089,583,484|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||14||13||2||15|
|Growth Rate (Year over Year)||-2.32%||24.52%||0.31%||23.55%|
ILMN estimates were raised through 2015, Credit Suisse said. Company can likely gain market share from its top competitor. Outperform rating and new $72 price target.
ILMN earnings estimates increased through 2014 given the first quarter beat, said UBS. The current earnings guidance seems conservative given recent momentum. Price target is now $67.
ILMN was upgraded to Buy from Neutral, UBS said. $61 price target. Re focus on commecial strength should drive upside.
These two stocks have been consolidating and now appear ready to move in opposite directions.
Shares of ILMN downgraded to Neutral from Outperform, Wedbush said. $52 price target. Diminished risk/reward due to gain in share price.
ILMN was upgraded from Neutral to Overweight, Piper Jaffray said. $61 price target. Company can continue to gain market share in next-generation sequencing.
ILMN was downgraded from Outperform to Neutral, Robert Baird said. $54 price target. Company faces more near-term challenges.
We are shifting from a multi-position, swing-trading approach to a shorter-term approach.
ILMN was upgraded from Market Perform to Outperform, Leerink Swann said. Company has multiple potential catalysts.
ILMN was placed on the U.S. focus list, according to Credit Suisse. Company is a market leader with its HiSeq machines.